Skip to content

Clinical trial of Validated Yoga Protocol on Polycystic ovarian Syndrome (PCOS)

Effect of Validated Yoga Protocol in the management of Polycystic ovarian Syndrome - NIL

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2023/09/057915
Enrollment
110
Registered
2023-09-21
Start date
Unknown
Completion date
Unknown
Last updated
2023-10-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E282- Polycystic ovarian syndrome

Interventions

Intervention1: Yoga Intervention: Validated Yoga module for 6 months, minimum 5 days a week, 60 minutes per session from online/offline mode Control Intervention1: Standard drug of PCOS: Tab Metformin

Sponsors

Banaras Hindu University
Lead Sponsor
Shringarika Mishra
Collaborator

Eligibility

Inclusion criteria

Inclusion criteria: Patients who satisfied the Rotterdam criterion (2/3 of the features) for PCOS will be included in the study. The following were the definitions of the three features. Oligo/amenorrhea: Absence of menstruation for 45 days or more and/or less than eight menses per year. Clinical hyperandrogenism, Modified Ferriman and Gallway (mFG) score of 6 or higher. Biochemical hyperandrogenism, serum LH and FSH ratio more than 2:1. Poly cystic ovaries: Presence of >10 cysts, 2-8 mm in diameter, usually combined with increased ovarian volume of >10 cm3, and an echo-dense stroma in pelvic ultrasound scan

Exclusion criteria

Exclusion criteria: Patients who use of oral contraceptives/hormone treatment/insulin-sensitizing agents within previous six weeks. Patients who have addiction of alcohol, smoking and any prior experience of yoga. Patients who have Hyperprolactinemia, thyroid abnormalities and non-classic adrenal hyperplasia, and those who did not consent for the study. Patients who have Primary ammenorheoa, Premature ovarian failure, absent ovary and uterus. The patients suffering from diabetes mellitus, hypertension, thyroid disorders, hyperprolactinemia, congenital adrenal hyperplasia, other gynaecological disorders, and renal failure. Patients with evidence of malignancy. Patients suffering from major systemic illness necessitating long term drug treatment (Rheumatoid arthritis, Psycho-Neuro-Endocrinal disorders, etc.) Patients who have a past history of Atrial Fibrillation, Coronary Artery Disease (CAD), Acute Coronary Syndrome, Myocardial Infarction, Stroke or Severe Arrhythmia in the last 6 months. Symptomatic patient with clinical evidence of Heart failure. Patients on prolonged ( > 6 weeks) medication with corticosteroids, antidepressants, anticholinergics, etc. or any other drugs that may have an influence on the outcome of the study. Patients who have completed participation in any other clinical trial during the past six (06) months. Any other condition which the doctor thinks may jeopardize the study.

Design outcomes

Primary

MeasureTime frame
To see the efficacy of validated Yoga Protocol on menstrual characteristics in pcos patientsTimepoint: 6 months with follow up of every 4th week

Secondary

MeasureTime frame
To assess the effect of validated Yoga module on Agni assessment scale, Hospital Anxiety & Depression Scale Perceived stress scale & quality of life in PCOS women at the end of 8th week 16th week 24th week. To assess the effect of validated Yoga module on anthropometric measurements (body weight, body mass index [BMI], chest circumference, waist circumference, hip circumference, mid-arm circumference, & waist–hip ratio) at the end of 8th week 16th week 24th week. To assess the effect of validated Yoga module on ovarian morphology as judged by ultrasound monitoring of the ovaries at 1st & 24th week To assess the effect of validated Yoga module on FSH, LH, TSH, PRL & Testosterone at 1st week and 24th week To assess the effect of validated Yoga module on CBC LFT Lipid Profile and Blood glucose level at 1st and 24th weekTimepoint: 6 Months

Countries

India

Contacts

Public ContactDr Mamta Tiwari

Banaras Hindu University

mamtat6@gmail.com9918733821

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026